RG6042 (previously known as IONIS-HTTRx) reduces the concentration of mutant huntingtin (HTT) levels in the cerebrospinal fluid of patients with HD without causing serious adverse events (Tabrizi et al., 2019). This evidence concerns the gene HTT and Huntington disease.